stockportfolio.pro
Perspective Therapeutics, Inc. (CATX)
Healthcare · Medical Devices · NYSE American
Perspective Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.76M | $5.92M | $7.31M | $9.68M | $10.05M | $10.79M | $0 | $1.43M | $1.45M | $884,000 |
| Gross profit | $838,000 | $1.84M | $3.05M | $5.12M | $5.12M | $4.62M | — | $1.43M | — | — |
| Net income | $-6.16M | $-6.70M | $-5.14M | $-3.45M | $-3.39M | $-7.27M | $-10.76M | $-46.51M | $-79.28M | $-103.12M |
| Net margin | -129.4% | -113.1% | -70.3% | -35.6% | -33.7% | -67.4% | — | -3243.2% | -5452.5% | -11665.3% |
Source: Perspective Therapeutics, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
Explore 16 years of Perspective Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CATX in your portfolio →
Perspective Therapeutics, Inc. financial history by metric
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Perspective Therapeutics, Inc. — frequently asked questions
What is Perspective Therapeutics, Inc.'s revenue?
Perspective Therapeutics, Inc. (CATX) reported revenue of $884,000 for fiscal year 2025, down 39.2% from the prior year, according to its SEC filings.
Is Perspective Therapeutics, Inc. profitable?
No — CATX reported a net loss of $-103.12M in fiscal 2025.
What is CATX's P/E ratio?
Perspective Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Perspective Therapeutics, Inc. growing?
CATX's revenue grew at roughly -38.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Perspective Therapeutics, Inc. have?
As of fiscal year 2025, CATX carried roughly $1.63M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Perspective Therapeutics, Inc.'s market cap?
Perspective Therapeutics, Inc. (CATX) has a market capitalization of about $339.29M, based on the latest data in our nightly-refreshed cache.
When does Perspective Therapeutics, Inc.'s fiscal year end?
CATX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Perspective Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.